HomeGNLX • NASDAQ
Genelux Corp
add
$2.58
3.61%
After Hours:(1.16%)+0.030
$2.61
Closed: May 23, 8:00:00 PM UTC-4 · USD · NASDAQ · Disclaimer
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 7.82M | -3.78% |
Net income | -7.49M | 4.56% |
Net profit margin | — | — |
Earnings per share | -0.21 | 27.59% |
EBITDA | -7.76M | 3.41% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 35.10M | 78.85% |
Total assets | 38.99M | 57.99% |
Total liabilities | 9.14M | -4.72% |
Total equity | 29.85M | — |
Shares outstanding | 37.30M | — |
Price to book | 3.11 | — |
Return on assets | -53.02% | — |
Return on capital | -65.38% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -7.49M | 4.56% |
Cash from operations | -5.44M | -24.83% |
Cash from investing | 3.51M | 307.51% |
Cash from financing | 9.57M | 1,290.55% |
Net change in cash | 7.64M | 242.64% |
Free cash flow | -2.66M | -103.16% |
Previous close
$2.49
Day range
$2.41 - $2.59
Year range
$1.60 - $5.89
Market cap
97.36M USD
Avg Volume
156.90K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Founded
2001
Headquarters
Website
Employees
24
